Eli Lilly's New GLP-1 Pill Vs. Wegovy, JPMorgan Initiates Coverage on Hims

Yahoo FinanceApr 24 11:00 ET

Spherix Global Insights Finds Specialty Split in Perceptions of Direct-to-Patient Platforms for Obesity Treatment

GlobeNewswireApr 24 10:18 ET

U.S. Stocks Movement | Eli Lilly and Co (LLY.US) Plummets 3.9% Against the Trend as Prescriptions for Oral Weight-Loss Drug Foundayo Lag Behind Novo-Nordisk A/S (NVO.US)

As of press time, the stock fell by 3.9%, trading at USD 881.648.

Zhitong FinanceApr 24 10:16 ET

Has Eli Lilly and Co fallen behind? The new generation of oral weight-loss drug Foundayo got off to a slow start, while Novo-Nordisk A/S surged ahead with five times the prescription volume.

Data shows that Foundayo generated 3,707 prescriptions in its second week of listing, while the oral version of Wegovy by Novo-Nordisk A/S recorded 18,410 prescriptions in its second week, indicating a significant gap. Eli Lilly and Co's share price fell 8% in pre-market trading, whereas Novo-Nordisk A/S's share price rose by 4%. Analysts noted that, in the field of oral weight-loss medications, Novo-Nordisk A/S may maintain its leading position with a more competitive product.

wallstreetcnApr 24 09:29 ET

4 Stocks to Watch on Friday: PG, LLY, MSFT, ABBV

Seeking AlphaApr 24 08:48 ET

Express News | US Prescriptions for Lilly's Foundayo Were 3,707 for Week Ended April 17- IQVIA Data Shared by Analyst Shows

ReutersApr 24 07:04 ET